In discussion with Dr. Erika Hamilton, covering the ESMO 2023 Breast Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. Hamilton:

- Keynote 756 – phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early stage, ER+/HER2- breast cancer, with better pCR seen in pembrolizumab arm

- TROPION-Breast01 – Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer, with better PFS and ORR favoring Dato-DXd

- Keynote 522 - Event Free Survival update with neoadjuvant and adjuvant pembrolizumab in TNBC, continue to show benefit

#ESMO #Pembrolizumab #Breast #Cancer #2023 #oncology #oncbrothers

Website: [ Ссылка ]

Twitter: [ Ссылка ]

Contact us at info@oncbrothers.com

свернуть